![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Paramount Global | NASDAQ:PARA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.1503 | -1.45% | 10.1997 | 10.19 | 10.20 | 10.66 | 10.15 | 10.33 | 15,105,089 | 22:47:34 |
By Ben Glickman
Micron Technology issued a better-than-expected outlook for the current quarter, forecasting a sharp rise in revenue. The memory-chip maker said strong pricing and demand for chips to support artificial intelligence boosted results in the fiscal first quarter, with the company reporting a narrower-than-expected loss. Shares rose 4.3%, to $82.11, after-hours.
Warner Bros. Discovery Chief Executive David Zaslav met with Paramount CEO Bob Bakish this week and discussed a possible merger, though no formal talks between the companies are under way. Warner Bros. Discovery shares fell 1.6% after-hours, while Paramount shares sank 1.7%.
Calliditas Therapeutics received full approval from the U.S. Food and Drug Adminstration for Tarpeyo as a treatment for patients with primary immunoglobulin A nephropathy. The treatment is the first fully FDA-approved treatment for IgAN, a disease in the kidneys, based on a measure of kidney function, the company said. Shares rose 25%, to $28, after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 20, 2023 18:45 ET (23:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Paramount Global Chart |
1 Month Paramount Global Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions